Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections-Reference-Cited by-同舟云学术

Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections

Published:2017-12-13 Issue:8 Volume:24 Page:1780-1784
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Kim Janice,Singh Harpreet,Ayalew Kassa,Borror Kristina,Campbell Michelle,Johnson Laura Lee,Karesh Alyson,Khin Ni A.,Less Joanne R.,Menikoff Jerry,Minasian Lori,Mitchell Sandra A.,Papadopoulos Elektra J.,Piekarz Richard L.,Prohaska Kevin A.,Thompson Susan,Sridhara Rajeshwari,Pazdur Richard,Kluetz Paul G.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported outcomes used actively in cancer patients undergoing antineoplastic treatment: A mini-review of the Danish landscape;Computational and Structural Biotechnology Journal;2024-12

2. Associations of tumor-related psychiatric symptoms and healthy behaviors with dynamic quality of life after hepatocellular carcinoma hepatectomy;Supportive Care in Cancer;2024-08-14

3. Adverse Event Reporting in Cancer Clinical Trials: Incorporating Patient-Reported Methods. A Systematic Scoping Review;The Patient - Patient-Centered Outcomes Research;2024-04-08

4. Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma;JAMA Network Open;2024-03-27

5. [Special issue PRO] Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework;Journal of Biopharmaceutical Statistics;2024-02-15